Hashimoto's Thyroiditis Beyond Thyroid Hormones: A Systematic Review of Autoimmunity, Inflammation, and Multidimensional Burden
Clinical Endocrinology · 2026-07 · 105 (1) · 3-13
DOI: 10.1111/cen.70114 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Endocrinology, online erschienen am 02.03.2026. Verfasst von Gaspare Alfì und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Hashimoto Disease, Inflammation, Thyroid Hormones, Autoimmunity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Background
Hashimoto's thyroiditis (HT) is the most common autoimmune thyroid disease. Although levothyroxine therapy effectively normalizes thyroid‐stimulating hormone (TSH) in most patients, persistent symptoms are frequently reported, suggesting that autoimmunity and inflammation contribute to reduced quality of life (QoL) independently of thyroid hormone levels.
Methods
According to PRISMA guidelines, we systematically searched for MEDLINE, Scopus, and Web of Science studies that assessed the association of thyroid autoimmunity, inflammatory markers, and QoL in adults with HT. Included designs were observational, interventional, and longitudinal studies that published qualified QoL outcomes and immune/inflammatory markers.
Results
Across diverse study designs, HT patients—typically euthyroid or receiving long‐term levothyroxine therapy—consistently reported lower QoL compared with controls, particularly in cognitive, affective, and vitality domains. Elevated anti‐thyroid antibodies (anti‐TPO, anti‐Tg) were negatively correlated with QoL, whereas TSH and thyroid hormone levels showed no consistent association. Interventional studies demonstrated that total thyroidectomy or therapies associated with reduced antibody titers were accompanied by improvements in fatigue and QoL. However, an important caveat must be emphasized. Some studies did not confirm a direct association between antibody levels and symptom severity, likely reflecting methodological variability and heterogeneity in QoL assessment tools.
Conclusion
There is evidence that HT exerts a multidimensional impact beyond endocrine dysfunction, with chronic autoimmunity and low‐grade inflammation contributing to impaired QoL. These findings should be taken into account and perhaps challenge a purely TSH‐centric model and call for a broader, patient‐centered approach that integrates immunological, psychological, and subjective outcomes. Properly designed longitudinal and interventional trials are required to establish causal pathways and support the personalization of therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
- International School of Advanced Studies, University of Camerino, Camerino, Italy.
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
ORCID-Profile: Gaspare Alfì, Valerio Caruso
Zitieren
APA
Alfì, G., Caruso, V., Grenno, G., Gemignani, A., Antonelli, A., Fallahi, P., & Ferrari, S. M. (2026). Hashimoto's Thyroiditis Beyond Thyroid Hormones: A Systematic Review of Autoimmunity, Inflammation, and Multidimensional Burden. Clinical Endocrinology, 105(1), 3-13. https://doi.org/10.1111/cen.70114
Vancouver
Alfì G, Caruso V, Grenno G, Gemignani A, Antonelli A, Fallahi P, et al. Hashimoto's Thyroiditis Beyond Thyroid Hormones: A Systematic Review of Autoimmunity, Inflammation, and Multidimensional Burden. Clinical Endocrinology. 2026;105(1):3-13. doi:10.1111/cen.70114
BibTeX
@article{Alf2026,
author = {Alfì, Gaspare and Caruso, Valerio and Grenno, Giovanna and Gemignani, Angelo and Antonelli, Alessandro and Fallahi, Poupak and Ferrari, Silvia Martina},
title = {Hashimoto's Thyroiditis Beyond Thyroid Hormones: A Systematic Review of Autoimmunity, Inflammation, and Multidimensional Burden},
journal = {Clinical Endocrinology},
year = {2026},
volume = {105},
number = {1},
pages = {3--13},
doi = {10.1111/cen.70114}
}
EUVIMED